The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

What can pharma glean from the first round of Transformation Funding for STPs?

Paul Midgley and Steve How, of Wilmington Healthcare, explain how the NHS is rewarding its most promising STPs and what they need from...

How will the NHS’s Capped Expenditure Process (CEP) affect pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach Trusts and Clinical Commissioning...

What does the NHS’s new medicines savings drive mean for pharma?

Steve How and Sue Thomas, of Wilmington Healthcare, explore how pharma should engage with CCGs on prescribing saving targets According to NHS...

How can pharma engage with Accountable Care Systems?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain how pharma can add value across care pathways The ‘Next Steps on the Five Year...

Vanguards: A blueprint for the future of the NHS

Last year, individual organisations and partnerships were invited to trial new ways of running primary and secondary care services in their local...

Window on a world of devolved health and social care

The Five Year Forward View (5YFV) has been dramatically changing the face of the NHS in 2016, particularly at a local level with the planned...

How can pharma help the NHS achieve ‘parity of esteem’ in mental health?

by Laurence Mascarenhas, Associate Director, Mental Health Services, NHiS Commissioning Excellence Mental illnesses are very common: For example,...

How can the NHS realise its vision of integrated care?

Sue Thomas and Paul Midgley, of NHiS, explain the changes needed to help the NHS deliver a more holistic, joined up experience for...

Latest Tweets from @Wilmhealthcare